Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers

Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers

Ovarian cancer is a lethal reproductive tumour affecting women worldwide. The advancement in presentation and occurrence of chemoresistance are the key factors for poor survival among ovarian cancer women. Surgical debulking was the mainstay of systemic treatment for ovarian cancer, which was follow...

Full description

Bibliographic Details
Main Authors:	Ghofraan Abdulsalam Atallah, Nirmala Chandralega Kampan, Kah Teik Chew, Norfilza Mohd Mokhtar, Reena Rahayu Md Zin, Mohamad Nasir bin Shafiee, Nor Haslinda binti Abd. Aziz
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	International Journal of Molecular Sciences
Subjects:	immunohistochemistry biomarkers platinum chemotherapy chemotherapy resistance disease relapse ovarian cancer
Online Access:	https://www.mdpi.com/1422-0067/24/3/1973

Similar Items

Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
by: Janisha Silva Raju, et al.
Published: (2021-03-01)

New Predictive Biomarkers for Ovarian Cancer
by: Ghofraan Abdulsalam Atallah, et al.
Published: (2021-03-01)

A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia
by: Lilit Harutyunyan, et al.
Published: (2024-03-01)

Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
by: Nicoletta Colombo
Published: (2014-12-01)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
by: Vanita Noronha, et al.
Published: (2012-01-01)

Synthesis and Pharmacological Evaluation of Modified Adenosines Joined to Mono-Functional Platinum Moieties
by: Stefano D'Errico, et al.
Published: (2014-07-01)

Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?
by: Paula Alfonso-Triguero, et al.
Published: (2023-05-01)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
by: Angelico D. Aputen, et al.
Published: (2023-04-01)

Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer
by: Alberto Romano, et al.
Published: (2020-05-01)

Platinum-based Cytotoxic Drugs in Hospital Effluent, Iasfahan, Iran
by: Samineh Dehghanpour, et al.
Published: (2020-02-01)

MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy
by: Nataša Lisica Šikić, et al.
Published: (2023-09-01)

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment
by: Donata Galbiati, et al.
Published: (2019-12-01)

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits
by: Abigail S. Zamorano, et al.
Published: (2017-11-01)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
by: Alex Molassiotis, et al.
Published: (2019-06-01)

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
by: Mohammad Jad Moussa, et al.
Published: (2024-02-01)

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
by: Jessa Gilda P. Pandy, et al.
Published: (2019-11-01)

Nanocarriers for platinum drug delivery
by: Qingfei Zhang, et al.
Published: (2023-06-01)

Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action
by: Ziwen Dai, et al.
Published: (2020-11-01)

The Clinical Analysis of First-Line Palitaxel Plus Platinum-Based Chemotherapy to Treat Elderly Non-Small Cell Lung Cancer
by: Tianqing CHU, et al.
Published: (2009-04-01)

Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
by: Fubin Zhu, et al.
Published: (2023-09-01)

Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer
by: Asami Ikeda, et al.
Published: (2020-11-01)

Nanocarriers containing platinum compounds for combination chemotherapy
by: Guihua Fang, et al.
Published: (2022-11-01)

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
by: Weiguang Gu, et al.
Published: (2023-11-01)

Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
by: Mohamed Elshebeiny, et al.
Published: (2016-09-01)

Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial
by: Sergei Krasny, et al.
Published: (2024-02-01)

Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers
by: Tibor A. Zwimpfer, et al.
Published: (2024-01-01)

IS HIPEC BENEFICIAL IN PLATINUM RESISTANT RELAPSED OVARIAN CANCER?
by: Nicolae Bacalbasa, et al.
Published: (2019-09-01)

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
by: Akihiro Ohmoto, et al.
Published: (2022-05-01)

Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01)

Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
by: Giovanni Tossetta
Published: (2022-10-01)

Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-β as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer
by: Jennifer Lim, et al.
Published: (2022-01-01)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
by: Florian Moik, et al.
Published: (2020-09-01)

PLA2G4A and ACHE modulate lipid profiles via glycerophospholipid metabolism in platinum-resistant gastric cancer
by: Menglin Chen, et al.
Published: (2024-03-01)

Vestibulotoxicity Associated With Platinum-Based Chemotherapy in Survivors of Cancer: A Scoping Review
by: Pattarawadee Prayuenyong, et al.
Published: (2018-09-01)

Efficacy of Bevacizumab Combined with Paclitaxel and Platinum-Based Chemotherapy in Advanced Metastatic Cervical Cancer and Its Effect on T Lymphocyte Subsets and Tumor Markers
by: WANG Lijun, et al.
Published: (2023-10-01)

Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer
by: Linlin Zhang, et al.
Published: (2022-12-01)

Where are we going with sentinel nodes mapping in ovarian cancer?
by: Nirmala Chandralega Kampan, et al.
Published: (2022-11-01)

DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?
by: Nuno Tiago Tavares, et al.
Published: (2022-06-01)

Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
by: CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin
Published: (2021-04-01)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
by: Omersa Daniel, et al.
Published: (2016-02-01)